IL143040A0 - A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystaline state - Google Patents

A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystaline state

Info

Publication number
IL143040A0
IL143040A0 IL14304099A IL14304099A IL143040A0 IL 143040 A0 IL143040 A0 IL 143040A0 IL 14304099 A IL14304099 A IL 14304099A IL 14304099 A IL14304099 A IL 14304099A IL 143040 A0 IL143040 A0 IL 143040A0
Authority
IL
Israel
Prior art keywords
meta
stable crystalline
crystalline region
producing particles
particles
Prior art date
Application number
IL14304099A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL143040A0 publication Critical patent/IL143040A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Oxygen, Ozone, And Oxides In General (AREA)
  • Saccharide Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Recrystallisation Techniques (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14304099A 1998-11-23 1999-11-22 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystaline state IL143040A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9804000A SE9804000D0 (sv) 1998-11-23 1998-11-23 New composition of matter
PCT/SE1999/002154 WO2000030614A1 (fr) 1998-11-23 1999-11-22 Production de particules a zone cristalline amorphe et/ou metastable convertie en etat cristallin

Publications (1)

Publication Number Publication Date
IL143040A0 true IL143040A0 (en) 2002-04-21

Family

ID=20413377

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14304099A IL143040A0 (en) 1998-11-23 1999-11-22 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystaline state
IL143040A IL143040A (en) 1998-11-23 2001-05-08 Process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL143040A IL143040A (en) 1998-11-23 2001-05-08 Process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state

Country Status (27)

Country Link
US (1) US6475524B1 (fr)
EP (1) EP1133285B1 (fr)
JP (1) JP4447169B2 (fr)
KR (1) KR100697780B1 (fr)
CN (1) CN1198592C (fr)
AT (1) ATE318583T1 (fr)
AU (1) AU767313B2 (fr)
BR (1) BR9915592A (fr)
CA (1) CA2349633C (fr)
CY (1) CY1105609T1 (fr)
CZ (1) CZ20011778A3 (fr)
DE (1) DE69930158T2 (fr)
DK (1) DK1133285T3 (fr)
EE (1) EE200100275A (fr)
ES (1) ES2258865T3 (fr)
HU (1) HUP0104182A2 (fr)
IL (2) IL143040A0 (fr)
IS (1) IS5946A (fr)
NO (1) NO20012514L (fr)
NZ (1) NZ511494A (fr)
PL (1) PL348523A1 (fr)
PT (1) PT1133285E (fr)
SE (1) SE9804000D0 (fr)
SK (1) SK7032001A3 (fr)
TR (1) TR200101424T2 (fr)
WO (1) WO2000030614A1 (fr)
ZA (1) ZA200103946B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0016002D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
EP1354581A4 (fr) * 2000-12-26 2007-07-04 Takeda Pharmaceutical Substance poreuse et son procede de fabrication
ATE323549T2 (de) * 2001-07-02 2006-05-15 Micro & Nano Materials Sagl Verfahren zur herstellung von nano- und mikro- teilchen
GB0126716D0 (en) * 2001-11-07 2002-01-02 Advanced Phytonics Ltd Method for the production of particles
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP2007520509A (ja) * 2004-02-06 2007-07-26 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト 抗コリン薬による、又は抗ヒスタミン薬、ホスホジエステラーゼ４、又はコルチコステロイドとの組み合わせによる鼻炎治療薬
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2005105765A1 (fr) 2004-05-05 2005-11-10 Renopharm Ltd. Donneurs d'oxyde nitrique et utilisations de ceux-ci
US7968575B2 (en) 2004-05-05 2011-06-28 Renopharm Ltd. Nitric oxide donors and uses thereof
US8134010B2 (en) 2004-05-05 2012-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
US7498445B2 (en) 2004-05-05 2009-03-03 Renopharm Ltd. Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
US7569586B2 (en) 2004-08-16 2009-08-04 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
JP5000095B2 (ja) * 2005-03-11 2012-08-15 花王株式会社 有機結晶粒子の製造方法
US8475845B2 (en) 2005-07-15 2013-07-02 Map Pharmaceuticals, Inc. Method of particle formation
DE102006030166A1 (de) * 2006-06-29 2008-01-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tempern
WO2009047935A1 (fr) * 2007-10-12 2009-04-16 Ono Pharmaceutical Co., Ltd. Particules fines
CN101918123B (zh) * 2007-12-07 2013-12-18 X喷雾微粒公司 生产微粒的方法与装置
JP5138670B2 (ja) * 2009-01-30 2013-02-06 三洋化成工業株式会社 樹脂粒子およびその製造方法
WO2010091198A1 (fr) 2009-02-06 2010-08-12 University Of Southern California Compositions thérapeutiques comprenant des monoterpènes
PT2453894E (pt) 2009-07-15 2016-02-02 Theravance Biopharma R&D Ip Llc Forma de base livre cristalina de um composto bifenilo
BR112012022209A2 (pt) 2010-03-03 2017-06-06 Neonc Tech Inc composições farmacêuticas compreendendo monoterpenos
EP2883543B1 (fr) 2010-08-27 2016-11-16 Neonc Technologies Inc. Compositions pharmaceutiques comprenant des carbamates d'alcool périllylique
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
DK2651864T3 (en) 2010-12-17 2016-09-05 Neonc Tech Inc Methods and devices for use of isoperillylalkohol
SI2968313T1 (en) 2013-03-15 2018-05-31 Verona Pharma Plc Combination of medicines
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
EP3142701B1 (fr) 2014-05-12 2018-06-27 Verona Pharma PLC Nouveau traitement
US9522918B2 (en) 2015-02-12 2016-12-20 Neonc Technologies, Inc. Pharmaceutical compositions comprising perillyl alcohol derivatives
CN110267538B (zh) 2016-11-30 2022-04-19 尼昂克技术公司 紫苏醇-3-溴丙酮酸缀合物和治疗癌症的方法
WO2019157195A1 (fr) 2018-02-08 2019-08-15 Neonc Technologies, Inc Procédés de perméabilisation de la barrière hémato-encéphalique

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
US5639441A (en) 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE69618938T2 (de) 1995-03-28 2002-10-31 Fidia Advanced Biopolymers, S.R.L. Nanosphären mit einem biokompatiblen polysaccharid
ES2316681T3 (es) 1997-03-20 2009-04-16 Schering Corporation Formas de dosificacion de aglomerados en polvo.

Also Published As

Publication number Publication date
TR200101424T2 (tr) 2001-12-21
IL143040A (en) 2009-09-01
CZ20011778A3 (cs) 2001-08-15
JP2002530319A (ja) 2002-09-17
NO20012514L (no) 2001-07-19
PT1133285E (pt) 2006-06-30
BR9915592A (pt) 2001-08-07
PL348523A1 (en) 2002-06-03
CA2349633C (fr) 2009-06-02
SK7032001A3 (en) 2001-11-06
DK1133285T3 (da) 2006-06-06
AU2010400A (en) 2000-06-13
ZA200103946B (en) 2002-10-30
NZ511494A (en) 2003-11-28
KR20010080534A (ko) 2001-08-22
KR100697780B1 (ko) 2007-03-21
EE200100275A (et) 2002-10-15
NO20012514D0 (no) 2001-05-22
SE9804000D0 (sv) 1998-11-23
DE69930158T2 (de) 2006-11-16
CN1198592C (zh) 2005-04-27
HUP0104182A2 (hu) 2002-03-28
IS5946A (is) 2001-05-18
ES2258865T3 (es) 2006-09-01
EP1133285B1 (fr) 2006-03-01
AU767313B2 (en) 2003-11-06
WO2000030614A1 (fr) 2000-06-02
ATE318583T1 (de) 2006-03-15
CN1328447A (zh) 2001-12-26
EP1133285A1 (fr) 2001-09-19
CY1105609T1 (el) 2010-07-28
CA2349633A1 (fr) 2000-06-02
JP4447169B2 (ja) 2010-04-07
DE69930158D1 (de) 2006-04-27
US6475524B1 (en) 2002-11-05

Similar Documents

Publication Publication Date Title
IL143040A0 (en) A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystaline state
CA2348084A1 (fr) Methode de cristallisation utilisant des fluides supercritiques ou des fluides sous-critiques
CA2149242A1 (fr) Derive de la quinuclidine pour le traitement de troubles inflammatoires et gastro-intestinaux
WO2001009118A3 (fr) Composes dithiolthione pour le traitement de troubles neurologiques et pour renforcer la memoire
WO2003024387A3 (fr) Methode et composition pharmaceutique destinees au traitement d'inflammations
CA2366268A1 (fr) Compositions pharmaceutiques pour le traitement de maladies du snc et d'autres maladies
WO2001041761A3 (fr) Compositions de valdecoxib
WO1996015786A3 (fr) Compositions orales contenant de l'ondansetron
CA2306393A1 (fr) Utilisation d'acide 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz£b,e]oxepine-2-acetique dans la production d'un medicament de traitement de troubles ophtalmiques inflammatoires non allergiques et de prevention de la neoformation de vaisseaux sanguins oculaires
NZ241210A (en) 16alpha,17alpha-butylidenedioxy-11b, 21-dihydroxypregn-4-ene-3,20-dione derivatives substituted in either or both the 6alpha- and 9alpha- positions by fluorine; pharmaceutical compositions, methods of preparation and treatment
CA2198706A1 (fr) Procedes de traitement de l'arthrite
CA2384448A1 (fr) Procede de traitement de la dermite seborrheique
NO962752L (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
WO2003066071A8 (fr) Formulations comprenant des medicaments psychotropes et du selenium
WO2000012045A3 (fr) Procede de traitement de troubles neuro-degeneratifs
CA2501738A1 (fr) Procede de traitement du syndrome de douleur pelvienne chronique par administration de gonadotropine chorionique
ATE99290T1 (de) Substituierte 4-amino-2-butinyl-harnstoffe und - thioharnstoffe sowie deren derivate als zentral wirkende muscarinische mittel.
WO2001042272A3 (fr) Forme cristalline d'eplerenone possedant une vitesse de dissolution accrue
WO2002005801A3 (fr) Compositions pharmaceutiques et procedes d'utilisation de ces dernieres
UA74388C2 (uk) Фармацевтичні композиції тизоксаніду і нітазоксаніду
WO2004014391B1 (fr) Utilisation de carboxamides pour le traitement des acouphenes
CA2279943A1 (fr) Traitement des affections de la peau
CN1069196C (zh) 利福平在制备治疗淋病用的药物中的应用
WO2002076437A3 (fr) Methodes de traitement de maladies neurodegeneratives, y compris de la maladie d'alzheimer
AU1400895A (en) 2,3-diaryl-1-benzopyrans for treating dermatitis